Latest News on RVTY

Financial News Based On Company


Advertisement
Advertisement

A 6-Day Losing Streak Has Revvity Stock Down 8.0%

https://www.trefis.com/stock/rvty/articles/626095/a-6-day-losing-streak-has-revvity-stock-down-8-0/2026-11-18
Shares of Revvity (RVTY) have experienced a 6-day losing streak, resulting in an 8.0% cumulative decline and erasing approximately $1.4 billion from its market value. While the S&P 500 also saw a decline during this period, Revvity's slide is largely stock-specific. The company's fundamentals present a mixed picture, with revenue growth below the S&P 500 Health Care median and a higher price-to-earnings ratio, suggesting a need for careful consideration before buying the dip.

Life Sciences and Laboratory Equipment Market Size, Share & Forecast 2036

https://www.factmr.com/report/life-sciences-and-laboratory-equipment-market
The Life Sciences and Laboratory Equipment Market is projected to reach USD 214.2 billion by 2036, growing at a CAGR of 6.9% from USD 109.9 billion in 2026. This growth is driven by expanding drug discovery, manufacturing investments by pharmaceutical companies, and increasing demand for analytical equipment and automated laboratory solutions. Key players are consolidating and integrating workflows to meet complex testing requirements and secure recurring revenue.

Solid Earnings Reflect Revvity's (NYSE:RVTY) Strength As A Business

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/solid-earnings-reflect-revvitys-nyservty-strength-as-a-busin
Revvity, Inc. recently reported robust earnings, but the market's reaction was subdued. The analysis suggests that investors might be overlooking promising details, especially considering a significant US$127m expense attributed to unusual items that are unlikely to recur. If these unusual expenses are not repeated, Revvity's future profitability is expected to be higher, with earnings per share already demonstrating a 33% annual growth over the last three years.

JP Morgan maintains Revvity at Neutral, raises price target to $165 from $160

https://www.tradingview.com/news/tradingview:c448ae23e7718:0-jp-morgan-maintains-revvity-at-neutral-raises-price-target-to-165-from-160/
JP Morgan has maintained its "Neutral" rating for Revvity (RVTY) and increased its price target from $160 to $165, suggesting a 6.9% upside from the recent closing price. This adjustment reflects a 3.1% rise in the target. Other analysts have also issued price targets ranging from $160 to $185 over the last 30 days.

Shared voting power covers 7.39 million Revvity (RVTY) shares across client portfolios.

https://www.stocktitan.net/sec-filings/RVTY/schedule-13g-a-revvity-inc-amended-passive-investment-disclosure-db59d7b2082d.html
Janus Henderson Group Ltd. has reported a 6.6% passive stake in Revvity (RVTY), beneficially owning 7,385,165 shares as of September 30, 2026. The firm exercises shared voting and dispositive power over these shares on behalf of its client Managed Portfolios, none of which individually own more than 5% of Revvity's common stock. Janus Henderson states that the Managed Portfolios, not the asset managers, retain the rights to dividends and sale proceeds from these securities.
Advertisement

Form 144 REVVITY For: 15 November By Investing.com

https://au.investing.com/news/stock-market-news/form-144-revvity-for-15-november-93CH-4771791
This article from Investing.com announces the filing of Form 144 for REVVITY, related to November 15. The brief piece includes the stock symbol RVTY and notes a minor price decline. The content primarily provides market data, related news, and promotional material from the Investing.com platform.

Form 144 REVVITY For: 15 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-revvity-for-15-november-93CH-4959292
This article from Investing.com announces the filing of Form 144 for REVVITY on November 15, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief notice highlights the company's stock symbol RVTY, which is shown with a slight decrease in value.

Form 144 REVVITY For: 15 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-revvity-for-15-november-93CH-2808601
Investing.com published an article titled "Form 144 REVVITY For: 15 November" on November 15, 2026, at 19:32 local time. The article provides information regarding a Form 144 filing for REVVITY (RVTY), a financial instrument that saw a -1.67% change.

Agilent Faces A Higher Bar As China Rebound And Pharma Reshoring Orders Get Their Second Test

https://finviz.com/news/422871/agilent-faces-a-higher-bar-as-china-rebound-and-pharma-reshoring-orders-get-their-second-test
Agilent Technologies is heading into its fiscal fourth-quarter report after consistently raising its outlook, leading to increased investor confidence. The key challenge is whether the strong performance drivers from last quarter—a China rebound, pharma acceleration, and early reshoring orders—can be sustained and carry the company into fiscal 2027 without further guidance lifts. Investors will closely watch for continued positive growth in China and broadening reshoring orders to validate the company's strong positioning.

Revvity Inc. stock underperforms Friday when compared to competitors

https://www.marketwatch.com/data-news/revvity-inc-stock-underperforms-friday-when-compared-to-competitors-562035cf-162c8e4941e4?mod=goog_fin_scmw
Shares of Revvity Inc. (RVTY) declined 1.67% on Friday, marking its fourth consecutive day of losses. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index fell. The stock closed at $154.39.
Advertisement

Form 8K Revvity Inc For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-revvity-inc-for-13-november-93CH-4956755
This article announces that Revvity Inc. filed a Form 8K on November 13, 2026. The filing is presented without further details, typical of an Investing.com news brief for SEC filings. The article also includes various market data and related news snippets.

After a roughly 16% headcount cut, Revvity (RVTY) outlines its 2027 growth outlook.

https://www.stocktitan.net/sec-filings/RVTY/8-k-revvity-inc-reports-material-event-8edc07e81c32.html
Revvity, Inc. (RVTY) hosted its 2026 Investor Day, detailing its strategy and financial outlook, including estimated 2026 revenue of ~$2.9 billion and adjusted EPS of ~$5.43. The company announced a long-range plan targeting ~6% organic growth for 2027 and double-digit adjusted EPS growth, noting a ~16% headcount reduction and ~25% global square footage reduction from 2023 to 2026. Revvity aims to drive growth through innovation, operational excellence, and strategic capital deployment, focusing on connecting biology, experimental data, and software for AI-enabled discovery.

Form 8K Revvity Inc For: 13 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-revvity-inc-for-13-november-93CH-4980916
This article announces that Revvity Inc. filed a Form 8K on November 13, 2026. The filing is an important regulatory disclosure for the company, and the brief piece includes the stock symbol RVTY and notes its current performance.

RVTY: Revvity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/revvity-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6789481
Revvity Inc. has filed an SEC Form 8-K announcing its 2026 Investor Day, scheduled for November 13, 2026, where CEO Prahlad Singh will provide updates on strategy, operations, and financial outlook. The company expects long-term above-market organic growth and provided key financial figures for 2026, including an estimated revenue of ~$2.9 billion. The filing also highlights positive aspects such as recurring revenue and share count reduction, alongside negatives like the planned divestiture of its Immunodiagnostics business in China.

Allarity paid $1 million to settle a $4.9 million liability plus accrued interest. Q4 earnings are expected.

https://www.stocktitan.net/news/ALLR/allarity-therapeutics-reports-third-quarter-2026-results-and-z18efv1igic7.html
Allarity Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $0.39 per share, primarily due to a one-time $3.2 million manufacturing charge. However, the company expects positive fourth-quarter earnings of $0.01–$0.04 per share, driven by a $1.0 million settlement payment that extinguished a $4.9 million liability with Novartis. Allarity also provided full-year 2026 loss guidance of $0.73–$0.76 per share and highlighted progress in its Phase 2 clinical programs and intellectual property.
Advertisement

Life Sciences revenue rises 11% at Revvity (RVTY), but Diagnostics moves the other way.

https://www.stocktitan.net/sec-filings/RVTY/10-q-revvity-inc-quarterly-earnings-report-49725440ee41.html
Revvity (RVTY) reported a 4% year-over-year revenue increase to $728.9 million and a net income of $62.3 million for the third quarter of fiscal year 2026. While the Life Sciences segment saw an 11% revenue rise, the Diagnostics segment experienced a 2% decrease. The company's gross margin improved to 57.4% due to a favorable product mix shift and restructuring benefits.

Corvus Pharmaceuticals advances with soquelitinib, funded through 2028, eyeing key clinical results in 2027.

https://pluang.com/en/news-feed/corvus-pharmaceuticals-daya-tahan-bukan-efikasi-puncak-adalah-produk-sejati
Corvus Pharmaceuticals is making progress with its drug soquelitinib, which shows promise for long-lasting remission in atopic dermatitis and PTCL, differentiating it from competitors due to its safety and durability. The company is funded through Q2 2028, minimizing immediate financing concerns, and anticipates significant clinical readouts, including Phase 3 trials, in 2027. This strong financial position and upcoming catalysts offer considerable upside potential for investors.

In Vitro Toxicology Testing - Global Strategic Business Report: Capitalize on the $14B-to-$27.4B Surge as Thermo Fisher Scientific, Merck, Eurofins and Bio-Rad Disrupt Testing by 2032

https://sg.finance.yahoo.com/news/vitro-toxicology-testing-global-strategic-145800531.html
The global in vitro toxicology testing market, valued at US$14 billion in 2025, is projected to reach US$27.4 billion by 2032, driven by regulatory shifts away from animal testing and advancements in human-relevant models, AI, and high-throughput screening. This growth is significantly influenced by pharmaceutical, biotechnology, cosmetics, and food safety industries adopting these technologies to accelerate safety assessments and reduce development costs. Key players like Thermo Fisher Scientific, Merck, Eurofins, and Bio-Rad are at the forefront of this market disruption.

Revvity Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-afeeed90-4d44011f91d3
Revvity Inc. (RVTY) shares rose 3.62% to $160.72 on a strong trading day for the stock market, outperforming the S&P 500 and Dow Jones Industrial Average. This marks the second consecutive day of gains for the stock.

A 36% narrower Q3 loss at Quanterix (QTRX) comes alongside a revenue decline.

https://www.stocktitan.net/sec-filings/QTRX/10-q-quanterix-corp-quarterly-earnings-report-d7c98c32b889.html
Quanterix (QTRX) reported a 13% decline in Q3 2026 revenue to $35 million year-over-year, largely due to weaker instrument demand and reduced Accelerator Laboratory services. However, the company narrowed its net loss by 36% to $21.6 million compared to the previous year, with nine-month revenue rising to $104.3 million. Despite a challenging capital funding environment affecting instrument sales, the company is implementing strategic changes, including a reorganized commercial structure and increased focus on Alzheimer's diagnostics, to accelerate revenue growth.
Advertisement

RVTY: Recovery Looks Firmer, But Better Growth And Margins Still Look Priced In

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nyse-rvty/revvity/caxc0fa3-rvty-operating-margins-and-buyback-plan-will-drive-share-recovery-ahead/updates/25-revvitys-analyst-price-target-has-been-revised-higher-from
Revvity's (RVTY) analyst price target has been revised higher to $154.00, driven by solid Q3 results and expectations for healthier revenue growth and margins. While bullish analysts highlight strong organic revenue and increasing AI-driven demand, cautious analysts believe current valuations already reflect an expected recovery, questioning further upside without sustained execution. The company reported strong Q3 2026 adjusted EPS and revenue beats, along with raised full-year guidance and new product launches.

Revvity Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-3f51f001-f255675b0cb4?mod=goog_fin_scmw
Shares of Revvity Inc. (RVTY) rose 2.84% on Friday, outperforming the S&P 500 Index which gained 0.31%, and the Dow Jones Industrial Average which fell 0.46%. This increase ended a two-day losing streak for the stock, with shares closing at $155.11.

ETFs Are Net Sellers of Revvity (RVTY) on Nov. 4

https://finance.yahoo.com/markets/stocks/articles/etfs-net-sellers-revvity-rvty-110324196.html
On November 4, Revvity (RVTY) experienced a net outflow of $25.3 million from ETFs, primarily driven by DFSV, which significantly cut its stake. This selling activity followed four consecutive days of net buying for the company's stock. Despite 25 ETFs buying shares compared to 7 selling, the selling amounts were larger, indicating a shift in ETF sentiment for Revvity.

Revvity, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-inc-just-beat-analyst-forecasts-and-analysts-have-be
Revvity, Inc. (NYSE:RVTY) recently surpassed analyst expectations for its quarterly report, with revenues reaching US$710m and statutory earnings per share outperforming by 13%. Despite these strong results, analysts have made no significant changes to their 2027 revenue and EPS forecasts, which remain at US$3.03b and US$2.86 respectively, and the consensus price target held steady at US$150. While Revvity's future growth is expected to improve compared to its past performance, it is still projected to lag behind the broader industry's revenue growth.

Barclays maintains Revvity at Equal-Weight, raises price target to $175 from $160

https://www.tradingview.com/news/tradingview:6c73e1038b218:0-barclays-maintains-revvity-at-equal-weight-raises-price-target-to-175-from-160/
Barclays has reiterated its "Equal-Weight" rating for Revvity and increased its price target from $160 to $175, representing a 9.4% hike. This new price target suggests a 7.0% upside from Revvity's closing price of $163.48 on November 3. Other analysts have recently issued ratings for Revvity, with price targets ranging from $160 to $180.
Advertisement

Stifel raises Revvity stock price target to $177 on AI demand

https://uk.investing.com/news/stock-market-news/stifel-raises-revvity-stock-price-target-to-177-on-ai-demand-93CH-4957432
Stifel has increased its price target for Revvity Inc (NYSE:RVTY) to $177 from $110, maintaining a Hold rating, due to the company's strong quarterly results and growing demand linked to artificial intelligence. The stock has seen significant appreciation, rising 89% in the past six months, with AI impact noted in high content screening and other business areas. Despite a perfect Piotroski Score, InvestingPro analysis suggests the stock is overvalued relative to its Fair Value, while BofA Securities also raised its price target to $185 following Revvity's impressive Q3 2026 earnings.

Stocks making big moves yesterday: Regal Rexnord, Camping World, Advanced Energy, Shopify, and Revvity

https://www.theglobeandmail.com/investing/markets/stocks/SHOP/pressreleases/8649540/stocks-making-big-moves-yesterday-regal-rexnord-camping-world-advanced-energy-shopify-and-revvity/
Several companies experienced significant stock movements on Tuesday following their third-quarter 2026 financial results. Regal Rexnord, Advanced Energy, and Revvity saw their stock prices rise due to strong earnings and raised guidance, while Camping World and Shopify faced declines after missing Wall Street expectations. The article highlights key financial figures and business updates for each company.

TD Cowen maintains Revvity at Buy, raises price target to $185 from $175

https://www.tradingview.com/news/tradingview:265570e3ab67e:0-td-cowen-maintains-revvity-at-buy-raises-price-target-to-185-from-175/
TD Cowen has reiterated its Buy rating for Revvity and increased its price target to $185 from $175, representing a 5.7% rise. This new target suggests a 13.2% upside from Revvity's closing price of $163.48 on November 3. Other analysts have recently issued price targets for Revvity ranging from $172 to $180.

Revvity Shares Touch 52-Week High as Raised Forecast, AI Demand Lift Life Sciences

https://finance.biggo.com/news/5427167b-a765-44ef-87c5-b8509c9f54f0
Revvity Inc. (NYSE:RVTY) reached a 52-week high after exceeding third-quarter earnings and revenue estimates and raising its full-year guidance. The company attributed its strong performance to recovering pharma and biotech demand, broadening AI-related orders, and robust growth in its Life Sciences segment, particularly Signals software. Management anticipates sustained momentum, with incremental margins exceeding 40% and strategic product launches further strengthening its market position.

Septerna selects SEP-204 for Graves' disease and TED treatment, plans Phase 1 trial in early 2027

https://pluang.com/en/news-feed/septerna-pilih-sep-204-kandidat-pengembangan-penyakit-graves-ted-data-preklinis
Septerna, Inc. has announced SEP-204 as its lead candidate for treating Graves' disease and thyroid eye disease (TED), an oral drug that inhibits the thyroid-stimulating hormone receptor (TSHR). Preclinical results have been promising, showing normalization of thyroid hormone levels and symptom reduction in animal models. The company plans to initiate Phase 1 clinical trials in healthy volunteers in early 2027, potentially offering a novel treatment that targets the root cause of these autoimmune diseases.
Advertisement

SolarEdge Technologies Inc earnings beat by $0.26, revenue fell short of estimates

https://www.investing.com/news/earnings/solaredge-technologies-inc-earnings-beat-by-026-revenue-fell-short-of-estimates-4998797
SolarEdge Technologies Inc (NASDAQ: SEDG) reported third-quarter EPS of $0.29, significantly beating analyst estimates of $0.03, though revenue at $326.1M fell short of the $331.12M consensus. The company's stock has seen a 3.53% increase in the last three months but is down 19.84% over the past year. Looking ahead, SolarEdge Technologies Inc provided Q4 2026 revenue guidance of $245.00M-$275.00M, which is below the analyst consensus of $317.70M.

Revvity Q3 Revenue Rises 7% as Adjusted Margin Expands

https://www.tradingkey.com/news/presentation/262270941-
Revvity Inc. reported a strong third quarter in 2026, with pro forma revenue increasing 7% year-over-year to $710 million, driven by robust performance in its Life Sciences and Diagnostics segments. The company's adjusted operating margin expanded significantly due to volume leverage, a favorable product mix, and operational efficiencies. Revvity also provided its full-year 2026 guidance, projecting approximately 5% organic revenue growth and adjusted earnings per share between $5.40 and $5.45.

Revvity rises on full-year guidance boost

https://www.tradingview.com/news/seekingalpha:e324125d7094b:0-revvity-rises-on-full-year-guidance-boost/
Revvity's stock surged approximately 11% following the company's decision to increase its 2026 revenue and profit forecasts. This guidance boost came after Revvity reported strong Q3 financial results, exceeding both revenue and non-GAAP EPS expectations. The company's life sciences business saw significant growth, though its diagnostics segment experienced a slight decline.

Revvity Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:abb6cf081094b:0-revvity-q3-earnings-call-highlights/
Revvity (RVTY) reported strong third-quarter results, surpassing expectations with 7% pro forma organic growth driven by robust demand in Life Sciences and Diagnostics, and increasing interest in AI-related research tools. The company saw broad-based growth in Life Sciences, particularly in Signals Software and pharma/biotech sales, with AI demand extending beyond high-content screening. Revvity also raised its full-year organic growth and earnings outlook, demonstrating strong financial performance and strategic expansion into new technologies.

Agilent Technologies, Inc. (A) Stock forecasts

https://au.finance.yahoo.com/research/reports/ARGUS_3730_QuantitativeReport_1792540800000
Agilent Technologies, Inc. (A) received a "Raising target price to $190.00" rating from Argus on October 21, 2026. The company, originally spun out of Hewlett-Packard, is described as a leading life science and diagnostic firm with a current price of $175.46. The report suggests an upgrade for premium screener tools and exclusive reports.
Advertisement

Danaher Corporation (DHR) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_2892_AnalystReport_1793212640000
Argus has updated its price target for Danaher Corporation (DHR) to $260. Danaher is a diversified life sciences and diagnostics company with global operations, supporting the biopharma industry. The company, a component of the S&P, currently has a stock price of $230.11.

AbCellera Stock After Phase 2 Win In Menopause Symptoms Has The Bull Case Changed?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-stock-after-phase-2-win-in-menopause-symptoms-has
AbCellera Biologics' stock is being re-evaluated after positive Phase 2 data for its antibody ABCL635, targeting vasomotor symptoms in postmenopausal women. This marks a crucial clinical signal for the company's antibody discovery platform, potentially leading to a revenue-generating product. While this strengthens the long-term investment narrative, the company still faces challenges with funding, profitability, and competition in a capital-intensive and crowded market.

Revvity Inc (RVTY) (Q3 2026) Earnings Call Highlights: Strong Organic Growth and Raised ...

https://ca.finance.yahoo.com/news/revvity-inc-rvty-q3-2026-230525122.html
Revvity Inc (RVTY) reported strong Q3 2026 earnings, with 7% pro forma organic growth and adjusted EPS of $1.37, surpassing guidance. The company raised its full-year organic growth and EPS outlook, driven by robust performance in its Life Sciences segment and emerging AI-related demand. Despite some headwinds in APAC and China, Revvity demonstrated strong free cash flow and an improved leverage ratio, with a positive outlook for the coming quarters.

Revvity, Inc. Stock 12‑Month Price Target Raised to $150.43, Implies 1% Downside

https://www.tradingview.com/news/tradingview:a53ec7fa6b1cd:0-revvity-inc-stock-12-month-price-target-raised-to-150-43-implies-1-downside/
Analysts have increased Revvity, Inc.'s average 12-month price target to $150.43 from $149.36, with individual forecasts ranging from $110 to $180 per share. This updated target suggests a 1% potential downside from the Nov. 2 closing price. The consensus rating for RVTY remains "Hold" among 21 analysts.

Vanda Pharmaceuticals to present at multiple healthcare investor conferences in November 2026

https://pluang.com/en/news-feed/vanda-pharmaceuticals-ikuti-konferensi-investor-november-2026
Vanda Pharmaceuticals announced its participation in several healthcare investor conferences throughout November 2026, including events in New York City and London. The company will hold fireside chats at the Stifel 2026 Healthcare Conference and Jefferies Global Healthcare Conference, providing updates on its progress and strategies. Live webcasts and archived recordings will be available on Vanda's website.
Advertisement

Revvity Edges Past Q3 2026 Estimates, Posts $1.38 EPS, Revenue Up 4%

https://news.alphastreet.com/revvity-edges-past-q3-2026-estimates-posts-1-38-eps-revenue-up-4/
Revvity, Inc. (RVTY) reported strong Q3 2026 results, with adjusted EPS of $1.38 and revenue of $728.9 million, both exceeding analyst expectations. The diagnostics and research company saw significant growth in its Life Sciences segment and raised its full-year EPS guidance. Despite the positive financial performance, the stock traded down 3.4%, indicating market skepticism or profit-taking.

Altria vs. Philip Morris: Higher Yield or Faster Dividend Growth for Retirees?

https://247wallst.com/investing/2026/11/03/altria-vs-philip-morris-higher-yield-or-faster-dividend-growth-for-retirees/
This article compares Altria (MO) and Philip Morris International (PM) for retirees, highlighting their differing appeals. Altria offers a higher current dividend yield and trades at a steeper discount, making it attractive for immediate income. Philip Morris, however, boasts faster dividend growth, less leverage, and a stronger focus on smoke-free products, positioning it as a better long-term investment for income growth.

S&P 500 Top Movers for Today: Gainers and Losers

https://www.chartmill.com/news/APTV/Chartmill-57625-SP-500-Top-Movers-for-Today-Gainers-and-Losers
This article details the top gainers and losers among S&P 500 components for the day. It highlights companies like Fiserv, Revvity, and DuPont as significant gainers, often tied to recent earnings reports or positive business developments. Conversely, companies such as Gartner, Zebra Technologies, and Sysco were among the top losers, many of which also released their latest financial results.

Shopify, GE Vernova among market cap stock movers on Tuesday

https://www.investing.com/news/stock-market-news/shopify-ge-vernova-among-market-cap-stock-movers-on-tuesday-93CH-4996245
On Tuesday, several stocks experienced significant fluctuations, including Shopify and GE Vernova. The article highlights major movers across mega-cap, large-cap, mid-cap, and small-cap categories, detailing their percentage changes and reasons for movement, such as earnings beats, raised guidance, or disappointing outlooks.

Revvity Stock Hits 52-Week High - Here's Why

https://www.tradingview.com/news/benzinga:bdae73527094b:0-revvity-stock-hits-52-week-high-here-s-why/
Revvity Inc. (RVTY) stock reached a new 52-week high after reporting better-than-expected third-quarter results and raising its full-year earnings outlook. The growth was driven by strong demand from pharmaceutical and biotech customers, as well as increasing demand for AI-related technologies. The company also announced an updated fiscal 2026 pro forma adjusted earnings forecast and revenue outlook, excluding its China immunodiagnostics business.
Advertisement

Revvity Stock Hits 52-Week High - Here's Why

https://www.benzinga.com/markets/earnings/26/11/62832878/revvity-stock-hits-52-week-high-heres-why
Revvity Inc. (NYSE: RVTY) stock reached a new 52-week high after reporting stronger-than-expected third-quarter results and increasing its full-year earnings forecast. Growth was fueled by robust demand from pharmaceutical and biotech customers, as well as increasing interest in AI-related technologies. The company beat analyst estimates for adjusted earnings per share and revenue, prompting an upward revision of its fiscal 2026 outlook.

Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday

https://www.benzinga.com/trading-ideas/movers/26/11/62831428/fabrinet-everquote-lattice-semiconductor-fiserv-and-other-big-stocks-moving-higher-on-tuesday
On Tuesday, while the Dow Jones dipped, several major stocks experienced significant gains. Fabrinet, EverQuote, Lattice Semiconductor, and Fiserv were among the companies that saw their shares rise following better-than-expected quarterly financial results and, in some cases, optimistic future guidance. Other notable gainers included Ibotta Inc, Xtend AI Robotics, Aehr Test Systems, and Graphic Packaging Holding Co, all reporting strong financial performance or strategic achievements.

Revvity Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-49017b09-32b67d97ca8e
Shares of Revvity Inc. (RVTY) rose 7.84% to $163.48 on Tuesday, outperforming the S&P 500 Index which gained 0.36%, and the Dow Jones Industrial Average which fell 0.38%. This increase broke a two-day losing streak for the stock.

Revvity (NYSE:RVTY) surprises with strong Q3 2026, stock soars

https://stockstory.org/us/stocks/nyse/rvty/news/earnings/revvity-nyservty-surprises-with-strong-q3-2026-stock-soars
Revvity (NYSE:RVTY) exceeded Wall Street's revenue and adjusted EPS expectations for Q3 2026, with revenue climbing 10.3% year-on-year to $728.9 million and non-GAAP profit reaching $1.37 per share. The company raised its full-year revenue and adjusted EPS guidance, leading to a 5% surge in its stock immediately after the results were announced. Despite a history of weak long-term revenue and declining operating margins, recent two-year trends show improved organic revenue growth.

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

https://finance.yahoo.com/healthcare/articles/revvity-shares-jump-nearly-6-144539188.html
Revvity, Inc. (NYSE:RVTY) reported stronger-than-expected third-quarter 2026 earnings and revenue, leading to a nearly 6% jump in shares during premarket trading. The health sciences technology company exceeded analyst forecasts with adjusted earnings per share of $1.37 and revenue of $729 million, driven by strong performance in both its Life Sciences and Diagnostics segments. Consequently, Revvity raised its full-year 2026 earnings and revenue guidance, reflecting confidence in continued business momentum despite the pending divestiture of its China Immunodiagnostics business.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement